Do analysts rate PFSA or ICCM?

IceCure Medical has a consensus target price of $30.00, indicating a potential upside of 2,627.27%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, PFSA or ICCM?

IceCure Medical has higher revenue and earnings than Profusa. IceCure Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 8.66 -$35.82M -$5.62 thousand N/A IceCure Medical $3.95M 0.95 -$15.06M -$8.52 N/A

Is PFSA or ICCM more profitable?

Profusa has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Profusa's return on equity of 0.00% beat IceCure Medical's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% IceCure Medical -427.67% -174.26% -112.58%

Do analysts prefer INBS or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate PFSA or MBAI?

MBody AI has a consensus price target of $10.00, indicating a potential upside of 206.75%. Given MBody AI's stronger consensus rating and higher possible upside, analysts clearly believe MBody AI is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MBody AI 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, PFSA or MBAI?

MBody AI has lower revenue, but higher earnings than Profusa. MBody AI is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 8.66 -$35.82M -$5.62 thousand N/A MBody AI N/A N/A $4.14M -$7.42 N/A

Is PFSA or MBAI more profitable?

Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% MBody AI N/A N/A N/A

Do analysts rate AEMD or PFSA?

Aethlon Medical currently has a consensus price target of $1.50, suggesting a potential downside of 75.21%. Given Aethlon Medical's stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AEMD or PFSA more profitable?

Profusa's return on equity of 0.00% beat Aethlon Medical's return on equity. Company Net Margins Return on Equity Return on Assets Aethlon Medical N/A -123.08% -99.28% Profusa N/A N/A -1,731.09%

Do analysts rate PFSA or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PFSA or BJDX more profitable?

Profusa's return on equity of 0.00% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% Bluejay Diagnostics N/A -125.00% -99.79%

Profusa (PFSA) Competitors

$1.42 -0.07 (-4.70%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.48 +0.06 (+3.87%)

As of 10/9/2026 07:38 PM Eastern

Compare

PFSA vs. ICCM, INBS, MBAI, AEMD, and BJDX

Should you buy Profusa stock or one of its competitors? Profusa's main competitors and comparable companies include IceCure Medical (ICCM), Intelligent Bio Solutions (INBS), Check-Cap (MBAI), Aethlon Medical (AEMD), and Bluejay Diagnostics (BJDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Profusa compare to IceCure Medical?

Profusa (NASDAQ:PFSA) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, IceCure Medical had 3 more articles in the media than Profusa. MarketBeat recorded 5 mentions for IceCure Medical and 2 mentions for Profusa. Profusa's average media sentiment score of 0.00 equaled IceCure Medical'saverage media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
IceCure Medical	Neutral

9.8% of Profusa shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 15.0% of Profusa shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profusa has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Profusa has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Profusa's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
IceCure Medical	-427.67%	-174.26%	-112.58%

IceCure Medical has higher revenue and earnings than Profusa. IceCure Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	8.66	-$35.82M	-$5.62 thousand	N/A
IceCure Medical	$3.95M	0.95	-$15.06M	-$8.52	N/A

IceCure Medical has a consensus target price of $30.00, indicating a potential upside of 2,627.27%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

IceCure Medical beats Profusa on 8 of the 15 factors compared between the two stocks.

How does Profusa compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Intelligent Bio Solutions has a beta of 4.31, indicating that its share price is 331% more volatile than the broader market. Comparatively, Profusa has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Profusa's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Profusa	N/A	N/A	-1,731.09%

Intelligent Bio Solutions has higher revenue and earnings than Profusa. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.20	-$12.43M	-$9.02	N/A
Profusa	$100K	8.66	-$35.82M	-$5.62 thousand	N/A

In the previous week, Intelligent Bio Solutions and Intelligent Bio Solutions both had 2 articles in the media. Intelligent Bio Solutions' average media sentiment score of 0.00 equaled Profusa'saverage media sentiment score.

Company	Overall Sentiment
Intelligent Bio Solutions	Neutral
Profusa	Neutral

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by insiders. Comparatively, 15.0% of Profusa shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Intelligent Bio Solutions beats Profusa on 7 of the 12 factors compared between the two stocks.

How does Profusa compare to MBody AI?

Profusa (NASDAQ:PFSA) and MBody AI (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

MBody AI has lower revenue, but higher earnings than Profusa. MBody AI is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	8.66	-$35.82M	-$5.62 thousand	N/A
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A

Profusa has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, MBody AI has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
MBody AI	N/A	N/A	N/A

MBody AI has a consensus price target of $10.00, indicating a potential upside of 206.75%. Given MBody AI's stronger consensus rating and higher possible upside, analysts clearly believe MBody AI is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, MBody AI had 1 more articles in the media than Profusa. MarketBeat recorded 3 mentions for MBody AI and 2 mentions for Profusa. Profusa's average media sentiment score of 0.00 equaled MBody AI'saverage media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
MBody AI	Neutral

9.8% of Profusa shares are owned by institutional investors. Comparatively, 1.1% of MBody AI shares are owned by institutional investors. 15.0% of Profusa shares are owned by insiders. Comparatively, 0.5% of MBody AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

MBody AI beats Profusa on 8 of the 12 factors compared between the two stocks.

How does Profusa compare to Aethlon Medical?

Aethlon Medical (NASDAQ:AEMD) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Aethlon Medical and Aethlon Medical both had 2 articles in the media. Aethlon Medical's average media sentiment score of 0.75 beat Profusa's score of 0.00 indicating that Aethlon Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Aethlon Medical	Positive
Profusa	Neutral

Aethlon Medical has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Profusa has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

2.0% of Aethlon Medical shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 0.6% of Aethlon Medical shares are held by company insiders. Comparatively, 15.0% of Profusa shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aethlon Medical has higher earnings, but lower revenue than Profusa. Aethlon Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aethlon Medical	N/A	N/A	-$7.15M	-$34.97	N/A
Profusa	$100K	8.66	-$35.82M	-$5.62 thousand	N/A

Aethlon Medical currently has a consensus price target of $1.50, suggesting a potential downside of 75.21%. Given Aethlon Medical's stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa's return on equity of 0.00% beat Aethlon Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aethlon Medical	N/A	-123.08%	-99.28%
Profusa	N/A	N/A	-1,731.09%

Summary

Aethlon Medical beats Profusa on 7 of the 12 factors compared between the two stocks.

How does Profusa compare to Bluejay Diagnostics?

Profusa (NASDAQ:PFSA) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Profusa's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

Profusa has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, Profusa had 1 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 2 mentions for Profusa and 1 mentions for Bluejay Diagnostics. Profusa's average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
Bluejay Diagnostics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics has lower revenue, but higher earnings than Profusa. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	8.66	-$35.82M	-$5.62 thousand	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

9.8% of Profusa shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 15.0% of Profusa shares are held by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Profusa and Bluejay Diagnostics tied by winning 5 of the 10 factors compared between the two stocks.

Get Profusa News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFSA vs. The Competition

Export

Metric	Profusa	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$900K	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	0.00	25.57	274.15	26.16
Price / Sales	8.66	83.25	635.98	113.06
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	0.00	5.93	11.21	6.34
Net Income	-$35.82M	$146.18M	$3.50B	$381.90M
7 Day Performance	-15.98%	-0.38%	-0.90%	-1.41%
1 Month Performance	-43.20%	-2.02%	-4.44%	-3.48%
1 Year Performance	N/A	5.08%	6.96%	1.16%

Profusa Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFSA Profusa	0.2769 of 5 stars	$1.42 -4.7%	N/A	N/A	$900K	$100K	N/A	2	Short Interest Increase Gap Down
ICCM IceCure Medical	2.7135 of 5 stars	$1.62 +1.6%	$52.50 +3,150.8%	-96.2%	$5.45M	$3.38M	N/A	66	Short Interest Decrease Gap Up High Trading Volume
INBS Intelligent Bio Solutions	1.0394 of 5 stars	$1.67 +2.5%	N/A	-86.5%	$5.41M	$4.22M	N/A	10	Short Interest Decrease Gap Up
MBAI Check-Cap	2.3325 of 5 stars	$3.54 -5.6%	$10.00 +182.5%	N/A	$5.16M	N/A	N/A	85	Gap Down
AEMD Aethlon Medical	1.1841 of 5 stars	$6.52 +2.2%	$1.50 -77.0%	-83.6%	$4.54M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PFSA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profusa (PFSA) Competitors

PFSA vs. ICCM, INBS, MBAI, AEMD, and BJDX

How does Profusa compare to IceCure Medical?

Summary

How does Profusa compare to Intelligent Bio Solutions?

Summary

How does Profusa compare to MBody AI?

Summary

How does Profusa compare to Aethlon Medical?

Summary

How does Profusa compare to Bluejay Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profusa (PFSA) Competitors

PFSA vs. ICCM, INBS, MBAI, AEMD, and BJDX

How does Profusa compare to IceCure Medical?

Does the media prefer PFSA or ICCM?

Do insiders and institutionals believe in PFSA or ICCM?

Which has more risk & volatility, PFSA or ICCM?

Is PFSA or ICCM more profitable?

Which has preferable earnings & valuation, PFSA or ICCM?

Do analysts rate PFSA or ICCM?

Summary

How does Profusa compare to Intelligent Bio Solutions?

Which has more volatility & risk, INBS or PFSA?

Do analysts prefer INBS or PFSA?

Is INBS or PFSA more profitable?

Which has higher valuation & earnings, INBS or PFSA?

Does the media refer more to INBS or PFSA?

Do institutionals and insiders have more ownership in INBS or PFSA?

Summary

How does Profusa compare to MBody AI?

Which has stronger earnings & valuation, PFSA or MBAI?

Which has more risk & volatility, PFSA or MBAI?

Is PFSA or MBAI more profitable?

Do analysts rate PFSA or MBAI?

Does the media prefer PFSA or MBAI?

Do insiders and institutionals have more ownership in PFSA or MBAI?

Summary

How does Profusa compare to Aethlon Medical?

Does the media favor AEMD or PFSA?

Which has more volatility and risk, AEMD or PFSA?

Do insiders & institutionals hold more shares of AEMD or PFSA?

Which has better valuation and earnings, AEMD or PFSA?

Do analysts rate AEMD or PFSA?

Is AEMD or PFSA more profitable?

Summary

How does Profusa compare to Bluejay Diagnostics?

Is PFSA or BJDX more profitable?

Which has more risk & volatility, PFSA or BJDX?

Does the media prefer PFSA or BJDX?

Do analysts rate PFSA or BJDX?

Which has stronger valuation & earnings, PFSA or BJDX?

Do institutionals and insiders believe in PFSA or BJDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools